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Recent advances in the evaluation and management ofintracerebral hemorrhage (ICH) include: the identifica-
tion of molecular markers that correlate with events in its
early course, complications, and outcome; the impact of
previous treatment with antiplatelet or anticoagulant agents
on the outcome after ICH; the analysis of the results of the
large international STICH (Surgical Trial in Intracerebral
Hemorrhage) study; and the publication of the results of the
recombinant activated Factor VII trial in ICH.
Molecular Markers of ICH Complications,
Course, and Outcome
Recent research interest in ICH has attempted to produce a
better understanding of the events that occur early in its
course, including hematoma growth, development of perihe-
matoma edema, and the resultant tissue injury, factors that
can cause early neurological deterioration and can have
impact on its long-term outcome.1–3 These interrelated pro-
cesses are accompanied by a cascade of events that correlate
with elevation of certain molecular markers in serum.
The process of perihematoma edema formation starts early
after ICH onset, generally within 3 hours,4 and it increases
gradually in severity for at least 72 hours.5 Several mecha-
nisms in sequence contribute to the formation of edema,
including: a first phase of clot retraction with extrusion of
serum; a second phase (for the first 2 days) of activation of
the coagulation cascade with production of thrombin; and a
final phase (after 3 days from onset) of red blood cell lysis
with hemoglobin-induced neuronal damage.5 The central role
of thrombin in promoting perihematoma edema has been
documented in both experimental6 and human7 ICH, with
evidence of reduced edema formation after administration of
thrombin inhibitors. The deleterious effects of thrombin in the
perihematoma tissues are mediated by inflammation, cytotox-
icity, and disruption of the blood-brain barrier.8–10 The
molecular correlates of perihematoma edema include ele-
vated levels of glutamate, tumor necrosis factor-,
interleukin-1, and intercellular adhesion molecule-1, but only
tumor necrosis factor- levels are independently associated
with volume of perihematoma edema. High levels of serum
glutamate correlate with poor neurological outcome after
ICH.11
Another set of markers that play an important role in the
complications and outcome of ICH are the matrix metallopro-
teinases (MMPs). These are proteolytic, zinc-dependent en-
zymes that degrade the endothelial basal lamina.12 Serum levels
of the MMP-9 form of these enzymes are correlated with initial
edema volume and subsequent enlargement after ICH onset.13
The MMPs, especially MMP-9, have recently been shown to
play a role in the hemorrhagic complications that may follow
use of tissue plasminogen activator (tPA) for acute ischemic
stroke. Baseline elevations of MMP-9 were an independent
predictor of ICH in patients treated with intravenous tPA.14 In
addition, a documented correlation between serum glucose
levels and MMP-9 titers15 may possibly explain the observa-
tion that baseline hyperglycemia has been associated with an
increased risk of symptomatic ICH after intravenous16,17 and
intra-arterial18 thrombolysis. Another potential marker of
increased hemorrhagic risk after thrombolysis is cellular
fibronectin, a glycoprotein confined to the vascular endothe-
lium. An elevated plasma level of cellular fibronectin may
indicate endothelial damage as the potential mechanism for
the observed increased risk of hemorrhagic complications
after treatment with tPA.19
Effect of Regular Previous-Use of
Anticoagulants or Aspirin on
Outcome After ICH
Incidence of ICH is higher than that of subarachnoid
hemorrhage, increases exponentially with age, and is
higher in men than in women.20 Most spontaneous hema-
tomas are attributed to chronic arterial hypertension.21
Other independent risk factors for ICH are alcohol consump-
tion and anticoagulant treatment, and the risk is increased also
with aspirin-use, thrombolytic therapy, use of amphetamines
or cocaine, cigarette smoking, and diabetes mellitus.20–24
Coagulation disorders and bleeding tendency (eg, thrombo-
cytopenia) are rare causes of ICH. These factors increase risk
for ICH especially in young and middle-aged adult people,
whereas amyloid angiopathy becomes a common mechanism
with advanced age.
Case-fatality rate and functional outcome of survivors are
determined independently by the severity of the bleeding as
assessed by the initial level of consciousness, volume of
hematoma, presence of intraventricular blood, and location of
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hematoma (subcortical and cerebellar hematomas are associ-
ated with a better prognosis than deep hemispheric ones).25
Among the risk factors for ICH, patient age and possibly
amount of alcohol consumed before ICH are independent risk
factors for poor functional outcome. Anticoagulant treatment
(warfarin) and, recently, use of antiplatelet treatment before
ICH have been shown to increase the likelihood of death.26,27
In a population-based study, prior use of either warfarin or
aspirin increased the risk of death after ICH, independently
from the severity of bleeding.26 Warfarin-use is associated
with severe bleeding and large hematoma size already present
at hospital admission.26 Although intensity of anticoagulation
may be associated with ICH risk, it does not independently
predict death after ICH. Aspirin users with ICH do not have
a more severe bleeding than nonusers at admission, but
aspirin-use may lead to an increase in hematoma size after
admission.26,27 The relative risk of regular preictal aspirin-use
for death after ICH was 2.5 (95% CI, 1.3 to 4.6) as compared
with nonusers, after adjustment for confounding factors.26
Similar findings were shown in a retrospective hospital-based
study.27 Use of antiplatelet therapy (mostly aspirin) before
ICH was followed by acute deterioration (assessed as death or
need for emergency surgical evacuation of hematoma) with
an increase in hematoma volume (40%) within 2 days after
the onset of ICH. In this study, the authors did not determine
whether antiplatelet therapy impaired outcome beyond 2 days
from onset, thus remaining unknown how the initial increase
in hematoma volume or antiplatelet therapy affected overall
outcome. These 2 studies showed that aspirin/antiplatelet
therapy increases risk of death after ICH likely through a high
propensity to cause early increase in hematoma volume.
Overviews of antiplatelet trials have previously shown that
antiplatelet therapy increases the risk of fatal but not of
nonfatal hemorrhagic stroke.24 This risk, however, is smaller
than the benefits obtained when this therapy is used for
secondary prevention of ischemic cardiovascular and cere-
brovascular disease. These new results, however, suggest that
antiplatelet agents should not be used for primary prevention
of cerebrovascular disease.
Surgical Management of ICH: the
International STICH Trial Results
Operative treatment with clot removal is used for20% of all
patients with spontaneous ICH.20,25,26 Patients with a subcor-
tical or cerebellar hematoma at least 3 cm in diameter and
impaired consciousness are generally considered to benefit
from surgical hematoma evacuation, which reduces both
case-fatality and morbidity. Treatment of hematomas located
in the basal ganglia, the most common site of ICH, has been
controversial because of lack of evidence of benefit from
surgical treatment. The first prospective randomized con-
trolled trial of surgery for supratentorial spontaneous ICH
was published in 1961,28 and the next 2 studies, performed
during the computed tomography era, were published in
1989.29,30 None of these showed that surgical clot removal
improved the outcome of patients with hematomas located in
the basal ganglia. Endoscopic evacuation of hematomas in the
subcortex, but not in the putamen or thalamus, improved the
outcome of alert or somnolent patients; case-fatality was
reduced in large (volume 50 mL) hematoma cases and
functional outcome was better in those with smaller hemato-
mas.29 Evacuation of hematomas in the basal ganglia in
patients with Glasgow Coma Score (GCS) of 7 to 10 by
craniotomy reduced case-fatality, but the quality of life
remained poor in survivors.30 After a few additional random-
ized studies with small sample sizes and generally negative
results, the long-awaited results of the international STICH
study were recently published.31
STICH included 1033 patients (503 in the early surgery
group with median time from ICH onset to surgery of 30
hours [25th–75th percentile range, 16 to 49 hours], and 530 in
the initial conservative group) from 83 centers in 27 coun-
tries. A method of prognosis-based outcome evaluation was
used: patients were categorized at randomization into good
and poor prognosis groups according to a prognostic score
calculated from the GCS, hematoma volume, and patient age.
Outcome of these groups was assessed by different outcome
thresholds.
STICH did not show any definite beneficial effect from
early surgery (within 24 hours of randomization) on outcome
after supratentorial spontaneous ICH.31 Of patients random-
ized to early surgery, 26% had favorable outcome compared
with 24% randomized to initial conservative treatment. A
pre-specified subgroup analysis suggested a possible advan-
tage of surgical treatment for superficially located (1 cm
from the cortical surface) lobar hematomas. The overall
results of STICH, however, do not mean that surgery for all
ICH cases is useless. Included were only those patients for
whom the responsible neurosurgeon was uncertain about the
benefits of either treatment (ie, the clinical equipoise). Thus,
STICH excluded all those patients who were considered to need
early surgical clot evacuation by the responsible neurosurgeon.
Of patients randomized to initial conservative treatment,
140 patients (26%) were, however, operated on within a few
days (median 60 hours, range of 27 to 99 hours) after ICH,
mostly because of significant deterioration of their clinical
condition. At randomization, these patients had significantly
(P0.0001) larger hematomas (50 mL) and more likely
(P0.0001) had subcortical hematomas than those in the
initial conservative group. If this group of patients had not
been operated on, the overall benefits of surgery in the
subgroup with large subcortical hematomas may have been
more significant, particularly concerning mortality, as was
also shown in a previous randomized trial.29 It also remained
open whether this group of patients would not have deterio-
rated if they had been operated on soon after bleeding. For the
purpose of hematoma evacuation, craniotomy seemed to be a
better method than others.
In conclusion, the STICH results do not significantly
change current practice. Patients with a subcortical or cere-
bellar hematoma at least 3 cm in diameter and impaired
consciousness should be operated on, whereas the benefits of
surgery for patients with putaminal ICH in somnolent, stu-
porous or “semi-comatose” state (GCS 7 to 12) are still
uncertain. In the future, treatment of these hematomas with
minimally invasive methods may be useful if done early after
ICH onset, but control of hemostasis may be difficult because
the hematomas tend to continue to enlarge within the first 6
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hours after onset. According to the results of STICH and
other randomized studies, comatose patients (GCS 8) with
ICH in the basal ganglia or thalamus very unlikely benefit
from clot removal.
Medical Management: the Recombinant
Activated Factor VIIa Experience
The nonsurgical approaches to the treatment of ICH have
included a handful of trials that tested the value of steroids,32
osmotic diuretics,33 and hemodilution34 in reducing mortality
and disability. The negative results of these medical interven-
tions determined that attention continued to be focused on the
surgical option of drainage of the hematoma using a variety
of techniques. The recent publication of neutral results in the
large, prospective, and randomized international STICH
study31 coincided with the publication of the results of the
phase IIB trial of recombinant activated factor VIIa (rFVIIa)
in ICH.35 The study assessed several doses of the hemostatic
agent rFVIIa (NovoSeven, Novo Nordisk, Denmark) on their
effect of decreasing the early enlargement of the hematoma
(primary outcome); in addition, the effect of treatment on
several clinical secondary outcomes was measured at 90 days.
The results showed that each of the 3 doses of rFVIIa (40, 80,
160 g/kg) given within 4 hours of symptom onset were
followed by a significant reduction in hematoma growth in
comparison with placebo. The beneficial effect on early
hematoma growth was accompanied by improved survival
and favorable clinical outcomes in the treatment group. The
clinical effect of rFVIIa translated into a number needed to
treat of about 6 in order to prevent 1 unfavorable outcome.
The encouraging therapeutic benefit of rFVIIa has to be
balanced with the potential thrombotic complications, as the
frequency of predominantly arterial thromboembolic events
in the rFVIIa-treated group (7%) exceeded that of the control
group (2%). Because one-half of the 16 arterial events in the
rFVIIa group occurred in the highest dose (160 g/kg) group,
it is probable that the use of lower doses may lead to a
reduced risk for this complication. This approach is part of
the design of the on-going phase III FAST (rFVIIa in Acute
Hemorrhagic Stroke Treatment) international trial, in which
doses of 20 and 80 g/kg of rFVIIa are compared with
placebo. The documentation of a net benefit of rFVIIa in the
FAST trial will solidify the potential indication of rFVIIa in
patients with spontaneous ICH, and may justify consideration
of testing this agent in situations of high risk of ICH
enlargement, such as in warfarin-related ICH.
Other issues to consider include the fact that the benefit of
rFVIIa was highly significant when the treatment was initi-
ated within 3 hours of symptom onset, but those patients
treated more than 3 hours after onset had no difference in
hematoma growth in comparison with the placebo group.
This suggests that the time window available for intervention
is limited to this short interval, and treatment may thus be
beneficial for only a subset of patients with ICH. Another
issue of potential importance is that in the analysis of clinical
outcomes, there was no adjustment for blood pressure,36 a
factor known to affect the outcome of ICH.37 Attention to this
issue in future trials could identify interactions of rFVIIa with
blood pressure that could modify the magnitude of the benefit
in patients with ICH. Finally, the known enhancing of
thrombin generation on the surface of activated platelets by
rFVIIa38 raises a theoretical concern about thrombin-induced
increase in perihematoma edema6 in patients treated with this
hemostatic agent. However, the mean volume of the combi-
nation of ICH, intraventricular hemorrhage, and perihema-
toma edema at 72 hours remained essentially stable (and
significantly smaller than in the placebo group) across the 3
doses of rFVIIa, arguing against an edema-enhancing effect
of this agent.
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